Impacte del gènere I el sexe a la prevenció, tractament i pronòstic del càncer de pulmó


Enriqueta Felip Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology Universitat Autònoma de Barcelona

15 Novembre 2024

Cancer statistics 2020

International Agency for Research on Cancer


World Health Organization



In both sexes combined, lung cancer is:


- The 2nd most commonly diagnosed cancer (2206771, 11.4% of total cases)
- The leading cause of cancer death (1796144, 18% of total cancer deaths)

The 10 most common cancers in women 2020



Cigarette smoking

- Two-thirds of lung cancer deaths worldwide are attributable to smoking (*sung CA CANCER J CLIN 2021*)
- Women who smoke are ~25 times more likely to die from lung cancer than women who do not smoke (Thun NEJM 2013)
- Studies suggest female smokers are more likely to develop lung cancer compared to male when they smoke the same number of cigarettes (*De Matteis Am J Epidemiol 2013*)
- Controversy remains over whether female sex hormones play a role in the development of lung cancer regardless of smoking status (Jin Translat Oncol 2019)



Region-specific incidence rates by sex for lung cancers in 2020

22.9 51.6 Micronesia/Polynesia ---- Hundary 49.0 Eastern Europe 11.648.1 Eastern Asia 22.1 Southern Europe 43.1 16.4 Western Asia Turkey ---41.7 8.7 41.7 25.0 Western Europe Northern America 35.7 30.1 33.3 Northern Europe 26.8 Australia/New Zealand 28.1 22.7 27.5 9.3 Southern Africa 26.4 South-Eastern Asia 9.6 23.0 Caribbean 13.0 19.5 3.5 Northern Africa 17.8 South America 10.3 17.4 Melanesia 9.2 South Central Asia 9.7 3.5 **Central America** 6.8 4.0 Eastern Africa 4.2 3.0 Middle Africa 1.8 3.4 Western Africa 2.8 1.8 80 60 40 20 20 40 60 80 Age-standardized (W) incidence rate per 100,000 Males Females

Lung

Among women the highest incidence rates are in Northern America, Northern and Western Europe, Micronesia/Polynesia, and Australia/New Zealand, with Hungary having the highest country-specific rates

Rates are also high in Eastern Asia, largely reflecting the high burden among Chinese women despite their low smoking prevalence

Lung cancer in never-smokers

- 10%-40% of lung cancers are diagnosed in never-smokers
- The most common histological subtype of lung cancer ADC
- The demographics of lung ADC in neversmokers are distinct compared with smokers, with a greater proportion of women, and Asian or Pacific islanders
- EGFR mutations, more frequent in women vs men
- Causative factors for lung cancer in neversmokers are poorly understood

Lung adenocarcinoma promotion by air pollutants

A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a twostep process: an initiating step that induces mutations in healthy cells, followed by a promoter step that triggers cancer development¹. Here we propose that environmental particulate matter measuring 2.5 µm (PM_{2.5}), known to be associated with lung cancer risk, promotes lung cancer by acting on cells that harbour pre-existing oncogenic mutations in healthy lung tissue. Focusing on EGFR-driven lung cancer, which is more common in never-smokers or light smokers, we found a significant association between PM_{2.5} levels and the incidence of lung cancer for 32,957 EGFR driven lung cancer cases in four within-country cohorts. Functional mouse models revealed that air pollutants cause an influx of macrophages into the lung and release of interleukin-1β. This process results in a progenitor-like cell state within EGFR mutant lung alveolar type II epithelial cells that fuels tumorigenesis. Ultradeep mutational profiling of histologically normal lung tissue from 295 individuals across 3 clinical cohorts revealed oncogenic EGFR and KRAS driver mutations in 18% and 53% of healthy tissue samples, respectively. These findings collectively support a tumour promoting role for PM_{2.5} air pollutants and provide impetus for public health policy initiatives to address air pollution to reduce disease burden.

Nature. 2023 April 01; 616(7955): 159–167. doi:10.1038/s41586-023-05874-3.


Is lung cancer incidence in never-smokers increasing?

Retrospective study using registries from 3 US Institutions (1990 to 2013)

Demographic	Smokers (n = 10 854 total NSCLC + SCLC)	Never smokers (n = 1249 total NSCLC + SCLC)	Р*
Age, mean (SD), y	Į		
NSCLC	63.4 (12.9)	60.6 (16.7)	<.001
SCLC	61.7 (12.2)	63.3 (14.7)	.44
Sex, No. (% of NS	CLC cases)		
Female Male	3761 (82.5) 5619 (93.1)	798 (17.5) 415 (6.9)	<.001


*Two-sided P value from Student's t test for age and from chi-square test for sex. NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer.

Never-smoker NSCLC increased from 8.0% in 1990-95 to 14.9% in 2011-13 (P < .001)



Higher lung cancer incidence in young women than young men (US)

- Nationwide population-based incidence of lung cancer: 1995 – 2014
- Among persons born since the mid-1960s, incidence rates of lung cancer significantly higher among young women than among men
- Patterns not fully explained by sex differences in smoking behaviors)




Germline findings in lung cancer: Li-Fraumeni the main syndrome associated with lung cancer susceptibility

- Li-Fraumeni is a rare cancer susceptibility syndrome associated with germline pathogenic variants in the TP53
- The majority of Li-Fraumeni-associated lung ADC harbour EGFR somatic activating variants
- NSCLC and Li-Fraumeni syndrome (Mezquita JTO 2020)
 - ✓ 22 NSCLC patients, 64% women
 - ✓ Driver oncogenic alterations were observed in 90% of tumors, mainly EGFR mutated tumors
- Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation (*Serra Cancer Discov 2013*)
- Distinct NSCLC EGFR variants in a family with Li-Fraumeni syndrome: case report (Edmonson JTO CRR 2022)

Gender medicine and oncology: report and consensus of an ESMO workshop

A. D. Wagner^{1*}, S. Oertelt-Prigione², A. Adjei³, T. Buclin⁴, V. Cristina¹, C. Csajka^{4,5}, G. Coukos^{1,6}, U. Dafni^{1,7}, G.-P. Dotto^{8,9,10}, M. Ducreux¹¹, J. Fellay^{12,13}, J. Haanen¹⁴, A. Hocquelet¹⁵, I. Klinge¹⁶, V. Lemmens^{17,18}, A. Letsch^{19,20,21}, M. Mauer²², M. Moehler²³, S. Peters¹ & B. C. Özdemir^{1,10}



- Meaningful differences of both innate and adaptive immune responses between men and women explain different prevalence and mortality from autoimmune and infectious diseases
- Such sex-based differences of immune responses reflect complex interactions among genes, hormones, and environment

(Klein Nat Rev Immunol 2016, Ozdemir JCO 2018)

Sex and gender differences may influence cancer treatment outcomes in different ways All effects are modulated by age

Gender medicine and oncology: report and consensus of an ESMO workshop

A. D. Wagner^{1*}, S. Oertelt-Prigione², A. Adjei³, T. Buclin⁴, V. Cristina¹, C. Csajka^{4,5}, G. Coukos^{1,6}, U. Dafni^{1,7}, G.-P. Dotto^{8,9,10}, M. Ducreux¹¹, J. Fellay^{12,13}, J. Haanen¹⁴, A. Hocquelet¹⁵, I. Klinge¹⁶, V. Lemmens^{17,18}, A. Letsch^{19,20,21}, M. Mauer²², M. Moehler²³, S. Peters¹ & B. C. Özdemir^{1,10}

Ann Oncol 2019

Class/drug, name	Indication	<i>n</i> (men)/ (women)	Variability on CL (CV%)	Relative cha women vers	-
Angiogenesis inhil	bitors				
Aflibercept [47]	Advanced solid tumours	767/739	31%	Clfu Vfu	-16% -19%
Bevacizumab	Gastric cancer;	1101/949	26%	CL	−14% to −27%
[48, 49]	solid tumours				
Antineoplastic age	ents: antimetabolites				
5-Fluorouracil	GI malignancies;	74/42	22%-40%	CL CLmet	-14% to -27% -18%
[<mark>50, 51</mark>] and	metastatic colo-				
metabolite	rectal cancer				
Myeloablative age	nts				
Busulfan [52]	Marrow transplantation	904/689	22%	V	+7%
Antineoplastic age	ent: alkylating agents				
Temozolomide [53, 54]	Glioma, glioblast- oma, melanoma	303/177	5%-10%	CL	-19 to 27%
Mephalan [<mark>55</mark>]	Advanced malignancies	22/42	45%	CL	—19%
Trabectedin [56]	PD study	232/467	51%	V Keo	-17% +22%
Antineoplastic age	ents: alkaloids				
Paclitaxel [57, 58]	Solid tumours	159/160		CL Vmax	-30% +14%
lrinotecan (SN38) [59–61]	Solid tumours, glioblastoma	67/58	47%	CL	-30% to 38%
Antineoplastic age	ent: antibodies				
Rituximab [62]	Lymphoma	16/13	19%	CL	-21%

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

Fabio Conforti, Laura Pala, Vincenzo Bagnardi, Tommaso De Pas, Marco Martinetti, Giuseppe Viale, Richard D Gelber, Aron Goldhirsch Lancet Oncol 18

Immune checkpoint inhibitors improve OS for patients with advanced cancers such as melanoma and NSCLC, but the magnitude of benefit is sexdependent

	Line of treatment	Intervention (number of patients)	Control (number of patients)		HR (95% CI)
Melanoma					- 0- /
Hodi et al (2010) ³⁶	>1	Ipilimumab (n=137)	gp100 (n=136)		0·81 (0·55–1·20) 0·54 (0·37–0·77)
		Ipilimumab plus gp100 (n=403)	qp100 (n=136)		0.72 (0.52-0.99
					0.66 (0.50-0.87
Robert et al (2011) ³⁵	1	Ipilimumab plus dacarbazine (n=250)	Dacarbazine plus placebo (n=252)		0.86 (0.63-1.17 0.70 (0.55-0.90
Ribas et al (2013)41	1	Tremelimumab (n=328)	ICC (n=327)		0.81 (0.62-1.06
Robert et al (2015) ³⁹	1	Nivolumab (n=210)	Dacarbazine (n=208) —		0·93 (0·74–1·17 0·56 (0·33–0·95
Robert et al (2015)	1	Nivolomab (n=210)			0.34 (0.22-0.54
Robert et al (2015) ³⁷	>1	Pembrolizumab q2w (n=279)	Ipilimumab (n=278)		0.69 (0.46-1.04
		Pembrolizumab q3w (n=277)	lpilimumab (n=278)		0·57 (0·39–0·84 0·78 (0·50–1·21
		(1-277)			0.66 (0.46-0.9
Hodi et al (2016) ³⁸	1	Nivolumab plus Ipilimumab (n=95)	Ipilimumab plus placebo (n=47)		0.89 (0.36-2.19
Larkin et al (2018)40	>1	Nivolumab (n=272)			0.65 (0.33-1.26 1.07 (0.69-1.65
		(1 2/2)	(((- <u>1</u>)))		0.85 (0.62–1.17
Non-small-cell lung cancer Borghaei et al (2015) ⁴⁹	>1	Nivolumab (n=292)	Docetaxel (n=290)		0.78 (0.58–1.04
Bolghael et al (2015)	~1		Docetaxer (n=290)		0.73 (0.56-0.96
Brahmer et al (2015) ⁴⁷	>1	Nivolumab (n=135)	Docetaxel (n=137)		0.67 (0.36-1.25
Herbst et al (2016) ⁴⁵	>1	Pembrolizumab (n=690)	Docetaxel (n=343)		0·57 (0·41–0·78 0·69 (0·51–0·9
11e10st et al (2010)	~1	rembronzomab (n=090)	Docetaxer (II=345)		0.65 (0.52-0.8)
Reck et al (2016) ⁴⁴	1	Pembrolizumab (n=154)	ICC (n=151)		0.96 (0.56-1.6
Carbone et al (2017) ⁴³	1	Nivolumab (n=271)	ICC (n=270)		0·54 (0·36–0·80 1·15 (0·79–1·66
()			. ,		0.97 (0.74-1.26
Govindan et al (2017) ⁴⁸	1	Ipilimumab plus paclitaxel plus carboplatin (n=388)	Paclitaxel plus carboplatin plus placebo (n=361)		1·33 (0·84–2·11 0·85 (0·71–1·02
Small-cell lung cancer					
Reck et al (2016) ⁴²	1	Ipilimumab plus etoposide plus	Etoposide plus platinum plus		1.06 (0.81-1.37
Mesothelioma		platinum (n=478)	placebo (n=476)		1.07 (0.89–1.28
Maio et al (2017)50	>1	Tremelimumab (n=382)	Placebo (n=189)		1.12 (0.72–1.75
Head and neck cancer		Nitracharach (m. 240)			0.91 (0.73-1.13
Ferris et al (2016) ⁵³	>1	Nivolumab (n=240)	ICC (n=121)		0·93 (0·47–1·8 0·65 (0·48–0·8
Cohen et al (2017) ⁵⁴	>1	Pembrolizumab (n=247)	ICC (n=248)	-	1.03 (0.61-1.72
Renal cell carcinoma Motzer et al (2015) ⁵¹	>1	Nivolumab (n=410)	Everolimus (n=411)		0.73 (0.61-0.92
Stomach cancer	~1	Nivolomab (n=410)	Everolimus (n=411)		0·84 (0·57–1·24 0·73 (0·58–0·92
Kang et al (2017) ⁵⁵	>1	Nivolumab (n=330)	Placebo (n=163)		0.83 (0.56-1.23
Jrothelial cancer Bellmunt et al (2017) ⁵²	>1	Pembrolizumab (n=270)	ICC (n=272)		0·59 (0·46–0·7 0·78 (0·49–1·2·
	-1	(1-270)	ICC(II=2/2)		0.73 (0.56-0.9
Pooled estimate in women				\diamond	0.86 (0.79-0.9
Pooled estimate in men			🔲 Women	p _{beteroseneity} =0.0019	0.72 (0.65-0.7
			0·25	0·5 1·0 2·0 4·0	
				ours intervention Favours control	

Figure 2: Hazard ratios of death for patients assigned to intervention treatment, compared with those assigned to control treatment, by sex


Squares represent study-specific HRs. Horizontal lines indicate the 95% Cls. Diamonds indicate the meta-analytic pooled HRs, calculated separately in females and males, with their corresponding 95% Cls. The dashed vertical lines indicate the gender-specific pooled HRs. The p value for heterogeneity is from the meta-analysis of the interaction HRs and represents heterogeneity by patients' sex. gp100=glycoprotein 100. HR=hazard ratio. ICC=investigator's choice chemotherapy. q2w=every 2 weeks. q3w=every 3 weeks.

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

Fabio Conforti, Laura Pala, Vincenzo Bagnardi, Giuseppe Viale, Tommaso De Pas, Eleonora Pagan, Elisabetta Pennacchioli, Emilia Cocorocchio, Pier Francesco Ferrucci, Filippo De Marinis, Richard D. Gelber, Aron Goldhirsch

J Natl Cancer Inst 19


- A greater effect of anti– PD1 alone in men
- A greater effect for anti– PD1/ PDL1 plus CT in women



HRs of death according to sex and type of immunotherapeutic strategy

Sex differences in risk of severe AEs in patients receiving immunotherapy, targeted therapy, or CT in cancer clinical trials (Unger JCO 2022)

- In total, 23,296 patients (women, 37.9%; men, 62.1%) from 202 trials were analyzed
- Overall, 64.6% experienced one or more severe (G ≥3) AEs
- Women had a 34% increased risk of severe AEs compared with men (OR 1.34; P , .001), including a 49% increased risk among those receiving ICI (OR 1.49; P , .001)
- Women experienced an increased risk of severe symptomatic AEs among all treatments, especially ICI (OR 1.66; 95% CI, 1.37 to 2.01; P, .001)
- Women receiving CT experienced increased severe hematologic AE



CT lung cancer screening: findings from the NELSON trial

- NELSON, the second largest randomized controlled trial to demonstrate a reduction in lung cancer mortality with CT screening of people at high risk
- Overall, CT scanning decreased mortality by 24% in high-risk men and 33% in high-risk women over a 10year period

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER			IASLC 19th World Conference on Lung Cancer September 23–26, 2018 Toronto, Canada VCLC2018.IASLC.ORG #WCLC2018		
Lung car mortali rate rat (95% C	ity tio	Year 8	Year 9	Year 10	Women represents only 16% of population
Ť	MALES	0.75 P=0.015 (0.59-0.95)	0.76 P=0.012 (0.60-0.95)	0.74 P=0.003 (0.60-0.91)	
FI FI	EMALES	0.39 P=0.0037 (0.18-0.78)	0.47 P=0.0069 (0.25-0.84)	0.61 P=0.0543 (0.35-1.04)	Rand: 23-12-2003 – 06-07-2006 FU: 23-12-2003 – 31-12-2015 FU 94% complete year 10
Harry J. de Kon	ing, Erasmus	s MC, Public Health Rott	terdam		2018

Take home messages

- Lung cancer is the second leading cause of cancer-related deaths among women worldwide
- Lung cancer cases by smoking are preventable
- Two-thirds of lung cancer never smoker are women
- EGFRm more frequent in never females *vs* males
- Sex differences in the immune system and immune reactions
- Future opportunities to reduce cancer mortality through improvements in screening and early detection

Gràcies!!! enriqueta.felip@vallhebron.cat efelip@vhio.net